newsfilter
← Earnings
Earnings Releases·

Prelude Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue decreased 13% year-over-year to $5.647 million, while net loss narrowed significantly to $12.544 million ($0.12 per share) from $19.725 million in the prior year period, driven by a 32% reduction in R&D expenses to $14.83 million.
  • The company maintains a strong liquidity position with $142.7 million in cash and marketable securities, providing a runway to fund operations into the second quarter of 2028.
  • Clinical progress includes enrollment in Phase 1 studies for PRT13722 (HR+ breast cancer) and PRT12396 (PV/MF), with initial proof of concept data for PRT13722 anticipated in the second half of 2027 and a collaboration with Eli Lilly established for PRT13722.
  • Strategic focus remains on advancing first-in-class programs following the 2025 pause of SMARCA2 trials, while the JAK2V617F inhibitor program faces an exclusive option agreement with Incyte expiring in February 2027.
Company
PRELUDE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology